BetaEntity Annotation Prototype

Entity family

Browse clinical instruments

Named questionnaires, scales, scores, indices, and other clinical outcome assessments. Examples include PHQ-9, GAD-7, EQ-5D.

945articles mentioning clinical instruments
1,957clinical instrument mentions
41distinct clinical instruments extracted
0%of mentions human-reviewed

All extracted clinical instruments

Showing 1–41 of 41, ordered by supporting articles. Choose a clinical instrument to see its evidence.

Articles mentioning clinical instruments

945 articles · page 64 of 79
Patient Health Questionnaire-9Japan Registry of Clinical TrialsNagoya City University Clinical Research Review Board

…ion Questionnaire, Valuing Questionnaire), depressive symptoms (Patient Health Questionnaire-9), mental illness stigma (Mental Illness: Clinicians’ Attitudes …

ECOG Performance StatusHCB101non-Hodgkin lymphomaTAIPEI VETERANS GENERAL HOSPITAL Institutional Review BoardNational Taiwan University HospitalEastern Cooperative Oncology GroupHangzhou First People’s Hospital Ethics Committee

… tumors or non-Hodgkin lymphoma (NHL). Eligible patients had an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Using a Bayesian Optimal In…

ECOG Performance StatusDana-Farber Cancer InstitutePHASE ONE FoundationIL-12myeloid leukemiaIL-15IL-18PROCpembrolizumabDana-Farber/Harvard Cancer Center+6 more

…confined to the abdominopelvic cavity, adequate organ function, ECOG performance status ≤1, and suitable for peritoneal catheter insertion. Patients un…

ECOG Performance StatustislelizumabsintilimabInnoPCVnon-small cell lung cancerAffiliated Hospital of Guizhou Medical UniversityINV002Anti-PD-1 monoclonal antibody

…ing to RECIST 1.1 criteria. Enrolled patients must also have an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible patients received tislelizumab (200 mg, IV …

ECOG Performance Statusbasal cell carcinomacutaneous squamous-cell carcinomacutaneous squamous cell carcinomaUniversity of California Cancer CentersRELAnivolumabNIVOrelatlimab

…r free flap reconstruction, be checkpoint inhibitor naïve, with ECOG performance status of <2. Key exclusion criteria include recent radiation therapy …